Future of Recombinant Human Insulin in Global Diabetes Management - touchENDOCRINOLOGY

Thursday, May 11, 2017 Medical Gadgets
Email Print This Page Comment
Font : A-A+

LONDON, May 11, 2017 /PRNewswire/ --

Jean Claude Mbanya, Juergen Sandow, Wolfgang

Landgraf and David R Owens

European Endocrinology, 2017;13(1):21-5: https://doi.org/10.17925/EE.2017.13.01.21

     (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO )

Published recently in European

Endocrinology, the peer-reviewed journal from touchENDOCRINOLOGY, Jean Claude Mbanya, Juergen Sandow, Wolfgang Landgraf and David R Owens introduce biosynthetic human insulin and insulin analogues as the mainstay of insulin therapy for both type 1 and type 2 diabetes. However, access to human insulin at affordable prices remains a global issue. The world is experiencing an exponential rise in the prevalence of diabetes presenting an urgent need to establish effective diabetes therapy in countries burdened by inadequate health care budgets, malnutrition and infectious diseases. Recombinant human insulin has replaced animal insulins and animal-based semisynthetic human insulin thereby available in sufficient quantities and at affordable prices able to provide global access to insulin therapy. In many patients, analog insulins can offer additional clinical benefit, although at a considerably higher price thus severely restricting availability in low income countries. The approval process for recombinant human insulins (i.e. biosimilars) and analogue insulins is highly variable in the developing countries in contrast to Europe and in North America, where it is well established within a strict regulatory framework. This review aims to discuss the future access to human insulin therapy in a global context with an ever increasing burden of diabetes and significant economic implications.

The full peer-reviewed, open-access article is available here:

https://doi.org/10.17925/EE.2017.13.01.21

Disclosure: Jean Claude Mbanya is member of the Sanofi AMESA Diabetes Advisory Board. Juergen Sandow is a consultant to Sanofi Paris and Academic Research Associate. Wolfgang Landgraf is an employee of Sanofi-Aventis Germany. David Owens has received honoraria from Boehringer Ingelheim, Eli Lilly, Sanofi and Takeda for lectures and/or advisory boards.

Note to the Editor

touchENDOCRINOLOGY (a division of Touch Medical Media) publishes European Endocrinology, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of endocrinology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.

www.touchENDOCRINOLOGY.com

For inquires please contact: Nicola Cartridge - Editorial Director nicola.cartridge@touchmedicalmedia.com

Providing practical opinion to support best practice for busy healthcare professionals.

SOURCE touchENDOCRINOLOGY



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook